Jérémie Abtan1,2, Deepak L Bhatt3, Yedid Elbez1,2, Emmanuel Sorbets1,2, Kim Eagle4, Yasuo Ikeda5, David Wu6, Mary E Hanson6, Hakima Hannachi6, Puneet K Singhal6, Philippe Gabriel Steg1,2,7, Gregory Ducrocq1,2. 1. French Alliance for Cardiovascular Clinical Trials (FACT), DHU-FIRE, Hôpital Bichat (Assistance Publique-Hôpitaux de Paris), Université Paris-Diderot, Sorbonne-Paris Cité and INSERM U-1148, Paris, France. 2. Hôpital Avicenne (Assitance Publique-Hôpitaux de Paris) and Université Paris 13, Bobigny, France. 3. Brigham and Women's Hospital Heart & Vascular Center and Harvard Medical School, Boston, Massachusetts. 4. University of Michigan Cardiovascular Center, Ann Arbor, Michigan. 5. Department of Internal Medicine, Graduate School of Medicine Keio University, Tokyo, Japan. 6. Merck & Co., Inc., Kenilworth, New Jersey. 7. National Heart and Lung Institute, Institute of Cardiovascular Medicine and Science, Royal Brompton Hospital, Imperial College, London, United Kingdom.
Abstract
BACKGROUND: Although the rate of in-hospital ischemic events after myocardial infarction (MI) has dramatically decreased, long-term residual risk may remain substantial. However, most of the information on current residual risk is derived from highly selected randomized trials. HYPOTHESIS: In patients with previous MI and no prior ischemic stroke/transient ischemic attack (TIA), residual ischemic risk increases over time. METHODS: Using the international Reduction of Atherothrombosis for Continued Health (REACH) registry, we analyzed baseline characteristics and 4-year follow-up of patients with previous MI and no history of stroke/TIA to describe annual rates of recurrent ischemic events globally and by geography. The primary outcome was the composite of cardiovascular death, MI, or stroke. Multivariate analysis identified risk factors associated with recurrent ischemic events. RESULTS: Data from 16 770 patients enrolled at 5587 sites in 44 countries were analyzed. The rate of the primary outcome increased annually from 4.7% during year 1 to reach a 4-year rate of 15.1%. Compared with North America, Japan experienced lower ischemic event rates (P < 0.01), whereas Eastern Europe (P < 0.01) and the Middle East (P = 0.01) experienced higher ischemic event rates. The presence of congestive heart failure, polyvascular disease, diabetes, atrial fibrillation or flutter, and older age were associated with increased residual risk (all P < 0.01). Statin use was associated with lower ischemic risk (P < 0.01). CONCLUSIONS: In this study, residual ischemic risk after MI accrued progressively up to 4 years of follow-up, emphasizing the value of intensive secondary prevention strategies to minimize residual risk.
BACKGROUND: Although the rate of in-hospital ischemic events after myocardial infarction (MI) has dramatically decreased, long-term residual risk may remain substantial. However, most of the information on current residual risk is derived from highly selected randomized trials. HYPOTHESIS: In patients with previous MI and no prior ischemic stroke/transient ischemic attack (TIA), residual ischemic risk increases over time. METHODS: Using the international Reduction of Atherothrombosis for Continued Health (REACH) registry, we analyzed baseline characteristics and 4-year follow-up of patients with previous MI and no history of stroke/TIA to describe annual rates of recurrent ischemic events globally and by geography. The primary outcome was the composite of cardiovascular death, MI, or stroke. Multivariate analysis identified risk factors associated with recurrent ischemic events. RESULTS: Data from 16 770 patients enrolled at 5587 sites in 44 countries were analyzed. The rate of the primary outcome increased annually from 4.7% during year 1 to reach a 4-year rate of 15.1%. Compared with North America, Japan experienced lower ischemic event rates (P < 0.01), whereas Eastern Europe (P < 0.01) and the Middle East (P = 0.01) experienced higher ischemic event rates. The presence of congestive heart failure, polyvascular disease, diabetes, atrial fibrillation or flutter, and older age were associated with increased residual risk (all P < 0.01). Statin use was associated with lower ischemic risk (P < 0.01). CONCLUSIONS: In this study, residual ischemic risk after MI accrued progressively up to 4 years of follow-up, emphasizing the value of intensive secondary prevention strategies to minimize residual risk.
Authors: Sidney C Smith; Emelia J Benjamin; Robert O Bonow; Lynne T Braun; Mark A Creager; Barry A Franklin; Raymond J Gibbons; Scott M Grundy; Loren F Hiratzka; Daniel W Jones; Donald M Lloyd-Jones; Margo Minissian; Lori Mosca; Eric D Peterson; Ralph L Sacco; John Spertus; James H Stein; Kathryn A Taubert Journal: J Am Coll Cardiol Date: 2011-11-03 Impact factor: 24.094
Authors: Peter W F Wilson; Ralph D'Agostino; Deepak L Bhatt; Kim Eagle; Michael J Pencina; Sidney C Smith; Mark J Alberts; Jean Dallongeville; Shinya Goto; Alan T Hirsch; Chiau-Suong Liau; E Magnus Ohman; Joachim Röther; Christopher Reid; Jean-Louis Mas; Ph Gabriel Steg Journal: Am J Med Date: 2012-07 Impact factor: 4.965
Authors: Christopher P Cannon; Michael A Blazing; Robert P Giugliano; Amy McCagg; Jennifer A White; Pierre Theroux; Harald Darius; Basil S Lewis; Ton Oude Ophuis; J Wouter Jukema; Gaetano M De Ferrari; Witold Ruzyllo; Paul De Lucca; KyungAh Im; Erin A Bohula; Craig Reist; Stephen D Wiviott; Andrew M Tershakovec; Thomas A Musliner; Eugene Braunwald; Robert M Califf Journal: N Engl J Med Date: 2015-06-03 Impact factor: 91.245
Authors: Stephen D Wiviott; Eugene Braunwald; Carolyn H McCabe; Gilles Montalescot; Witold Ruzyllo; Shmuel Gottlieb; Franz-Joseph Neumann; Diego Ardissino; Stefano De Servi; Sabina A Murphy; Jeffrey Riesmeyer; Govinda Weerakkody; C Michael Gibson; Elliott M Antman Journal: N Engl J Med Date: 2007-11-04 Impact factor: 91.245
Authors: Lars Wallentin; Richard C Becker; Andrzej Budaj; Christopher P Cannon; Håkan Emanuelsson; Claes Held; Jay Horrow; Steen Husted; Stefan James; Hugo Katus; Kenneth W Mahaffey; Benjamin M Scirica; Allan Skene; Philippe Gabriel Steg; Robert F Storey; Robert A Harrington; Anneli Freij; Mona Thorsén Journal: N Engl J Med Date: 2009-08-30 Impact factor: 91.245
Authors: Etienne Puymirat; Tabassome Simon; Philippe Gabriel Steg; François Schiele; Pascal Guéret; Didier Blanchard; Khalife Khalife; Patrick Goldstein; Simon Cattan; Laurent Vaur; Jean-Pierre Cambou; Jean Ferrières; Nicolas Danchin Journal: JAMA Date: 2012-09-12 Impact factor: 56.272
Authors: Deepak L Bhatt; Eric D Peterson; Robert A Harrington; Fang-Shu Ou; Christopher P Cannon; C Michael Gibson; Neal S Kleiman; Ralph G Brindis; W Frank Peacock; Sorin J Brener; Venu Menon; Sidney C Smith; Charles V Pollack; W Brian Gibler; E Magnus Ohman; Matthew T Roe Journal: Eur Heart J Date: 2009-04-01 Impact factor: 29.983
Authors: Keith A A Fox; Kathryn Carruthers; Ph Gabriel Steg; Alvaro Avezum; Christopher B Granger; Gilles Montalescot; Shaun G Goodman; Joel M Gore; Ann L Quill; Kim A Eagle Journal: Eur Heart J Date: 2009-12-08 Impact factor: 29.983
Authors: Jérémie Abtan; Deepak L Bhatt; Yedid Elbez; Emmanuel Sorbets; Kim Eagle; Yasuo Ikeda; David Wu; Mary E Hanson; Hakima Hannachi; Puneet K Singhal; Philippe Gabriel Steg; Gregory Ducrocq Journal: Clin Cardiol Date: 2016-09-02 Impact factor: 2.882
Authors: Maria Sakalaki; Salim Barywani; Annika Rosengren; Lena Björck; Michael Fu Journal: BMC Cardiovasc Disord Date: 2019-11-06 Impact factor: 2.298
Authors: Sang Hun Lee; Myung Ho Jeong; Joon Ho Ahn; Dae Young Hyun; Kyung Hoon Cho; Min Chul Kim; Doo Sun Sim; Young Joon Hong; Ju Han Kim; Youngkeun Ahn; Jin Yong Hwang; Weon Kim; Jong Seon Park; Chang-Hwan Yoon; Seung Ho Hur; Sang Rok Lee; Kwang Soo Cha Journal: Korean J Intern Med Date: 2022-06-28 Impact factor: 3.165
Authors: Ahmed Alghamdi; Bander Balkhi; Abdulaziz Altowaijri; Nasser Al-Shehri; Lewis Ralph; Emily-Ruth Marriott; Michael Urbich; Fawaz Aljanad; Rima Aziziyeh Journal: Pharmacoecon Open Date: 2021-09-28